For example, HER2-targeted therapies such as trastuzumab have significantly improved outcomes in HER2-positive breast cancer [1], whereas they offer no benefit in triple-negative breast cancer (TNBC), which lacks expression of HER2, estrogen, and progesterone receptors. This evidence concerns the gene ERBB2 and breast cancer.